Tredje AP fonden Takes $7.34 Million Position in Jazz Pharmaceuticals PLC $JAZZ

Tredje AP fonden acquired a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 43,200 shares of the specialty pharmaceutical company’s stock, valued at approximately $7,344,000.

Other large investors also recently modified their holdings of the company. Hilltop National Bank bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $36,000. LRI Investments LLC bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $38,000. GoalVest Advisory LLC bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $51,000. Danske Bank A S bought a new position in shares of Jazz Pharmaceuticals in the third quarter valued at about $40,000. Finally, Caitong International Asset Management Co. Ltd raised its position in shares of Jazz Pharmaceuticals by 1,383.3% in the third quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 332 shares during the period. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $237.45 on Wednesday. Jazz Pharmaceuticals PLC has a twelve month low of $105.00 and a twelve month high of $238.55. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. The company has a 50-day simple moving average of $199.21 and a two-hundred day simple moving average of $178.13. The stock has a market capitalization of $14.90 billion, a price-to-earnings ratio of -11,866.57, a price-to-earnings-growth ratio of 0.41 and a beta of 0.27.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The business had revenue of $1.07 billion during the quarter. Analysts forecast that Jazz Pharmaceuticals PLC will post 20.75 EPS for the current year.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total value of $1,143,000.00. Following the transaction, the director directly owned 384,682 shares of the company’s stock, valued at $73,281,921. This trade represents a 1.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Patricia Carr sold 1,287 shares of the firm’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $182.94, for a total transaction of $235,443.78. Following the completion of the transaction, the chief accounting officer directly owned 6,512 shares in the company, valued at approximately $1,191,305.28. This represents a 16.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 74,015 shares of company stock worth $14,180,486. Corporate insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on JAZZ. Robert W. Baird set a $252.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Truist Financial upgraded shares of Jazz Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Piper Sandler lifted their price objective on shares of Jazz Pharmaceuticals from $219.00 to $232.00 and gave the stock an “overweight” rating in a research note on Thursday, March 19th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $188.00 to $307.00 in a research note on Tuesday. Finally, Raymond James Financial reiterated an “outperform” rating and issued a $239.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $238.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.